Fabre-Kramer and GSK get "not approvable" for gepirone ER

12 November 2007

Houston, USA-based Fabre-Kramer Pharmaceuticals and UK drug major GlaxoSmithKline have been issued with a "not approvable" letter by the Food and Drug Administration regarding the co-developed major depressive disorder drug, gepirone ER. The decision, which follows the submission of additional supporting data earlier this year (Marketletter May 14), is a setback for both companies, but particularly for GSK which had hoped that, following a series of high profile problems, gepirone would bolster its product range and match analysts' peak sales forecasts of between $800.0 million and $1.6 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight